Inhibition of CDK9 activity compromises global splicing in prostate cancer cells
Cyclin-dependent kinase 9 (CDK9) phosphorylates RNA polymerase II to promote productive transcription elongation. Here we show that short-term CDK9 inhibition affects the splicing of thousands of mRNAs. CDK9 inhibition impairs global splicing and there is no evidence for a coordinated response betwe...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Taylor and Francis
2021
|
| _version_ | 1797107880606826496 |
|---|---|
| author | Hu, Q Poulose, N Girmay, S Helevä, A Doultsinos, D Gondane, A Steele, RE Liu, X Loda, M Liu, S Tang, D Mills, IG Itkonen, HM |
| author_facet | Hu, Q Poulose, N Girmay, S Helevä, A Doultsinos, D Gondane, A Steele, RE Liu, X Loda, M Liu, S Tang, D Mills, IG Itkonen, HM |
| author_sort | Hu, Q |
| collection | OXFORD |
| description | Cyclin-dependent kinase 9 (CDK9) phosphorylates RNA polymerase II to promote productive transcription elongation. Here we show that short-term CDK9 inhibition affects the splicing of thousands of mRNAs. CDK9 inhibition impairs global splicing and there is no evidence for a coordinated response between the alternative splicing and the overall transcriptome. Alternative splicing is a feature of aggressive prostate cancer (CRPC) and enables the generation of the anti-androgen resistant version of the ligand-independent androgen receptor, AR-v7. We show that CDK9 inhibition results in the loss of AR and AR-v7 expression due to the defects in splicing, which sensitizes CRPC cells to androgen deprivation. Finally, we demonstrate that CDK9 expression increases as PC cells develop CRPC-phenotype both in vitro and also in patient samples. To conclude, here we show that CDK9 inhibition compromises splicing in PC cells, which can be capitalized on by targeting the PC-specific addiction androgen receptor.
|
| first_indexed | 2024-03-07T07:20:22Z |
| format | Journal article |
| id | oxford-uuid:cae00a00-b460-40ed-8991-6a8ed637be86 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T07:20:22Z |
| publishDate | 2021 |
| publisher | Taylor and Francis |
| record_format | dspace |
| spelling | oxford-uuid:cae00a00-b460-40ed-8991-6a8ed637be862022-09-30T07:00:36ZInhibition of CDK9 activity compromises global splicing in prostate cancer cellsJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:cae00a00-b460-40ed-8991-6a8ed637be86EnglishSymplectic ElementsTaylor and Francis2021Hu, QPoulose, NGirmay, SHelevä, ADoultsinos, DGondane, ASteele, RELiu, XLoda, MLiu, STang, DMills, IGItkonen, HMCyclin-dependent kinase 9 (CDK9) phosphorylates RNA polymerase II to promote productive transcription elongation. Here we show that short-term CDK9 inhibition affects the splicing of thousands of mRNAs. CDK9 inhibition impairs global splicing and there is no evidence for a coordinated response between the alternative splicing and the overall transcriptome. Alternative splicing is a feature of aggressive prostate cancer (CRPC) and enables the generation of the anti-androgen resistant version of the ligand-independent androgen receptor, AR-v7. We show that CDK9 inhibition results in the loss of AR and AR-v7 expression due to the defects in splicing, which sensitizes CRPC cells to androgen deprivation. Finally, we demonstrate that CDK9 expression increases as PC cells develop CRPC-phenotype both in vitro and also in patient samples. To conclude, here we show that CDK9 inhibition compromises splicing in PC cells, which can be capitalized on by targeting the PC-specific addiction androgen receptor. |
| spellingShingle | Hu, Q Poulose, N Girmay, S Helevä, A Doultsinos, D Gondane, A Steele, RE Liu, X Loda, M Liu, S Tang, D Mills, IG Itkonen, HM Inhibition of CDK9 activity compromises global splicing in prostate cancer cells |
| title | Inhibition of CDK9 activity compromises global splicing in prostate cancer cells |
| title_full | Inhibition of CDK9 activity compromises global splicing in prostate cancer cells |
| title_fullStr | Inhibition of CDK9 activity compromises global splicing in prostate cancer cells |
| title_full_unstemmed | Inhibition of CDK9 activity compromises global splicing in prostate cancer cells |
| title_short | Inhibition of CDK9 activity compromises global splicing in prostate cancer cells |
| title_sort | inhibition of cdk9 activity compromises global splicing in prostate cancer cells |
| work_keys_str_mv | AT huq inhibitionofcdk9activitycompromisesglobalsplicinginprostatecancercells AT poulosen inhibitionofcdk9activitycompromisesglobalsplicinginprostatecancercells AT girmays inhibitionofcdk9activitycompromisesglobalsplicinginprostatecancercells AT helevaa inhibitionofcdk9activitycompromisesglobalsplicinginprostatecancercells AT doultsinosd inhibitionofcdk9activitycompromisesglobalsplicinginprostatecancercells AT gondanea inhibitionofcdk9activitycompromisesglobalsplicinginprostatecancercells AT steelere inhibitionofcdk9activitycompromisesglobalsplicinginprostatecancercells AT liux inhibitionofcdk9activitycompromisesglobalsplicinginprostatecancercells AT lodam inhibitionofcdk9activitycompromisesglobalsplicinginprostatecancercells AT lius inhibitionofcdk9activitycompromisesglobalsplicinginprostatecancercells AT tangd inhibitionofcdk9activitycompromisesglobalsplicinginprostatecancercells AT millsig inhibitionofcdk9activitycompromisesglobalsplicinginprostatecancercells AT itkonenhm inhibitionofcdk9activitycompromisesglobalsplicinginprostatecancercells |